These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20504095)

  • 1. The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles.
    Kinay T; Tasci Y; Dilbaz S; Cinar O; Demir B; Haberal A
    Gynecol Endocrinol; 2010 Nov; 26(11):833-7. PubMed ID: 20504095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.
    Kolibianakis E; Bourgain C; Albano C; Osmanagaoglu K; Smitz J; Van Steirteghem A; Devroey P
    Fertil Steril; 2002 Nov; 78(5):1025-9. PubMed ID: 12413988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends.
    Checa MA; Prat M; Robles A; Carreras R
    Fertil Steril; 2006 Mar; 85(3):573-7. PubMed ID: 16500321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial thickness is related to miscarriage rate, but not to the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist.
    Detti L; Yelian FD; Kruger ML; Diamond MP; Rode A; Mitwally MF; Puscheck EE
    Fertil Steril; 2008 Apr; 89(4):998-1001. PubMed ID: 17678904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
    Cicek MN; Kahyaoglu I; Kahyaoglu S
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol.
    Rombauts L; Lambalk CB; Schultze-Mosgau A; van Kuijk J; Verweij P; Gates D; Gordon K; Griesinger G
    Fertil Steril; 2015 Oct; 104(4):884-890.e2. PubMed ID: 26187300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro fertilization stimulation protocol for normal responder patients.
    Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
    Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.